On the other hand, as TRAIL sensitization in this study was performed at relatively lower and shorter exposure that did not trigger cell apoptosis, there is a higher possibility that oral absorption of AXT might have a positive effect that sensitizes GBM tissues to TRAIL treatment. The gene discussed is CNTN2; the disease is glioblastoma.